Israel21c5d
Promising new drug could slow progression of ALS
A chance encounter with an inspiring ALS patient, prompted Alon Ben-Noon to set up NeuroSense Therapeutics, a startup ...
Walk to defeat ALS at Homewood Central Park happening Sept. 22
People living with ALS, family members, friends, caregivers and anyone affected by the disease will come together for the ...
Medscape6d
ALS Blood Test Promises Accurate, Earlier Diagnosis
A blood test has been shown to accurately identify patients with amyotrophic lateral sclerosis at early stages, which could ...
The Pharma Letter4d
Athira shifts focus to ALS drug after Alzheimer’s flop
Athira Pharma is refocusing efforts on ATH-1105 after its Alzheimer’s drug, fosgonimeton, failed to meet endpoints in the ...
Study finds genetic link between Parkinson's disease, ALS
People with rare genetic variants linked to degenerative brain disorders like Parkinson's disease are at increased risk of ...
Investing6d
Clene Inc. to discuss ALS drug with FDA by November end
Clene will present to the FDA’s Office on New Drugs, Office of Neuroscience, and DN1 review team, along with key opinion leaders in the field of ALS. The discussion will address questions on ALS ...
DeFiance on MSN6d
Verge Genomics and Ferrer Collaborate to Advance ALS Drug Candidate VRG50635 Globally
Verge Genomics and Ferrer have partnered to co-develop VRG50635, a promising AI-discovered drug for ALS treatment. Ferrer will develop and commercialize the drug in select global markets, while Verge ...
News Medical6d
iPSC-Based Neuromuscular and Neuronal Models for ALS and Drug Discovery
PSC-derived cells and micro-physiological systems provide significant advancements in enhancing neuronal disease models, ...
Targeting MS, ALS and more, Nura Bio adds on $68 million
ALS, MS, post-traumatic brain injury? This biotech company has a target choice to make for an upcoming clinical trial — and ...
Drugs which switch on vitamin A in the body may stave off MND, research suggests
Drugs that switch on vitamin A in the body may also help stave off conditions such as motor neurone disease (MND), raising ...
Investing6d
Clene Inc. to discuss ALS drug with FDA by November end
Clene will present to the FDA’s Office on New Drugs, Office of Neuroscience, and DN1 review team, along with key opinion leaders in the field of ALS. The discussion will address questions on ALS ...